Aurobindo Pharma announced that it received the approval of the Hon'ble National Company Law Tribunal, Hyderabad bench vide order dated 30 March 2021 for the modified scheme of amalgamation of wholly owned subsidiaries of Aurobindo Pharma viz., APL Healthcare and APL Research Centre and Aurozymes and Curepro Parenterals and Hyacinths Pharma and Silicon Life Sciences with Aurobindo Pharma.

Powered by Capital Market - Live News

Aurobindo Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 881.55, up 1.28% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.71% on the day, quoting at 14739.45. The Sensex is at 49683.89, down 0.9%. Aurobindo Pharma Ltd has gained around 0.9% in last one month.

Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has gained around 1.77% in last one month and is currently quoting at 12206.6, up 0.82% on the day. The volume in the stock stood at 7.89 lakh shares today, compared to the daily average of 19.97 lakh shares in last one month.

The benchmark April futures contract for the stock is quoting at Rs 886.85, up 1.33% on the day. Aurobindo Pharma Ltd is up 124.71% in last one year as compared to a 78.58% jump in NIFTY and a 75.14% jump in the Nifty Pharma index.

The PE of the stock is 17.1 based on TTM earnings ending December 20.

Powered by Capital Market - Live News

Aurobindo Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 851.3, down 1.32% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.07% on the day, quoting at 14945.05. The Sensex is at 50434.99, down 0.01%.Aurobindo Pharma Ltd has eased around 12.05% in last one month.Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has eased around 6.15% in last one month and is currently quoting at 12239.85, down 1.04% on the day. The volume in the stock stood at 5.64 lakh shares today, compared to the daily average of 25.26 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 853, down 1.34% on the day. Aurobindo Pharma Ltd jumped 89.11% in last one year as compared to a 42.9% rally in NIFTY and a 58.89% spurt in the Nifty Pharma index.

The PE of the stock is 16.97 based on TTM earnings ending December 20.

Powered by Capital Market - Live News

The Board of Aurobindo Pharma at its meeting held on 27 February 2021 has approved the following -

1. Transfer of all equity shares held in Lyfius Pharma, a wholly owned subsidiary of the Company, to Aurobindo Antibiotics, another wholly owned subsidiary of the Company.

2. Transfer of all equity shares held in Qule Pharma, a wholly owned subsidiary of the Company, to Aurobindo Antibiotics, another wholly owned subsidiary of the Company.

3. Transfer of business undertaking comprised in Unit-10, on a going concern basis, to APL Healthcare, a wholly owned subsidiary of the Company.

Powered by Capital Market - Live News